摘要:
The subject invention comprises a method for diagnosing a clinical event that occurs in a patient's tissue by conducting diagnostic tests on a patient sample obtained from a substance stream in contact with affected tissue. One of the diagnostic tests is an assay for a molecule released from the tissue during the clinical event, and another diagnostic test is an assay for a molecule that is present in the stream and is modified by the clinical event. The results of the assays are combined in an algorithm to provide a positive or negative diagnosis of the clinical event. In one embodiment, the clinical event is a myocardial infarction, the sample is blood or a component thereof, the molecule released from the affected tissue is a necrotic marker (e.g., troponin), and the modified molecule in the blood component is ischemia modified albumin. In another embodiment, the clinical event is an ischemic stroke, the sample is blood or a component thereof, the molecule released from the affected tissue is a necrotic marker (e.g., S1OOB), and the modified molecule in the blood component is ischemia modified albumin.
摘要:
The subject application comprises methods for determining the occurrence of an ischemic event in a subject by determining an ischemia score based on the amount of at least two ischemia modified albumin markers. The ischemia modified albumin markers include complexes of fatty acids bound to albumin, albumin molecules with open Cys34 sites, albumin molecules that are products of oxidation at Cys34, albumin molecules with altered conformation or altered divalent metal binding due to the conformational change or oxidation at Cys34, and albumin molecules that have been oxidized at the N-terminus. Also included in the invention are ligands to each of the foregoing ischemia modified albumin markers. Further included are methods of determining the occurrence of an ischemic event by determining the amount of fatty acid that is complexed to albumin in a patient sample. In another embodiment, an ischemic event is determined by quantitating the relative amounts of reduced and oxidized forms of albumin Cys34. In an additional embodiment, an ischemic event is determined by observing whether a shift in albumin conformation has occurred which would reflect oxidized Cys34. Further, the invention comprises a method of determining an ischemic event by determining the amount of metal ion bound to the albumin metal ion binding sites.
摘要:
The subject invention comprises a method for diagnosing a clinical event that occurs in a patient's tissue by conducting diagnostic tests on a patient sample obtained from a substance stream in contact with affected tissue. One of the diagnostic tests is an assay for a molecule released from the tissue during the clinical event, and another diagnostic test is an assay for a molecule that is present in the stream and is modified by the clinical event. The results of the assays are combined in an algorithm to provide a positive or negative diagnosis of the clinical event. In one embodiment, the clinical event is a myocardial infarction, the sample is blood or a component thereof, the molecule released from the affected tissue is a necrotic marker (e.g., troponin), and the modified molecule in the blood component is ischemia modified albumin. In another embodiment, the clinical event is an ischemic stroke, the sample is blood or a component thereof, the molecule released from the affected tissue is a necrotic marker (e.g., S1OOB), and the modified molecule in the blood component is ischemia modified albumin.
摘要:
The present invention relates to rapid methods for the detection of ischemic states and to kits for use in such methods. Provided for is a rapid method of testing for and quantifying ischemia based upon methods of detecting and quantifying the existence of an alteration of the serum protein albumin which occurs following an ischemic event; methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of circulating albumin, analysis and measurement of the ability of serum albumin to bind exogenous cobalt, detection and measurement of the presence of endogenous copper in a purified albumin sample and use of an immunological assay specific to the altered form of serum albumin which occurs following an ischemic event. Also taught by the present invention is the detection and measurement of an ischemic event by measuring albumin N-terminal derivatives that arise following an ischemic event, including truncated albumin species lacking one to four N-terminal amino acids or albumin with an acetylated N-terminal Asp residue.
摘要:
The present invention teaches a marker useful for detection and measurement of free radical damage. Specifically, the invention takes advantage of alterations which occur to the N-terminus of the albumin molecule, a circulating protein in human blood, in the presence of free radicals. These alterations effect the ability of the N-terminus of the albumin molecule to bind metals. Methods for detecting and quantifying this alteration include evaluating and quantifying the cobalt binding capacity of an albumin-containing sample, analysis and measurement of the ability of albumin to bind exogenous cobalt, detection and measurement of the presence of copper in a purified albumin sample and use of an immunological assay specific to the altered form of serum albumin which occurs following free radical damage. Also taught by the present invention is the use of the peptide Asp Ala His Lys and the compound Asp-Ala-His-Lys-R, wherein R is any chemical group capable of producing a detectable signal when a metal ion capable of binding to the N-terminus of naturally-occurring albumin is bound to the compound, for detection and quantitation of the marker. Methods of the present invention also include use of the marker as a "biochemical tag", thereby allowing for sensitive detection and measurement of the efficacy of clinical drugs and therapeutics which result in the generation of free radicals or which act to limit free radical damage. The marker also acts as a "biological tag" of a process implicated in a wide array of diseases and conditions and, accordingly, may be used to monitor and assess such diseases and conditions. Finally, the invention provides antibodies, immunoassays, and kits for use in detecting or quantitating the marker.
摘要:
Diagnostic test devices, including diagnostic strip tests, are provided in which identifying information and the test result are machine-readable. Also provided are methods for obtaining identifying information and test results from the diagnostic test devices.
摘要:
The subject invention comprises electrochemical methods and device for in vitro detection of an ischemic event in a patient sample. Following addition of a known amount of a transition metal ion to the patient sample, electrodes (2, 4, 6) are used to measure the current or potential difference of non-sequestered transition metal ion in the sample. The amount of non-sequestered transition metal ion in the sample reflects the degree of modification to albumin that is the result of an ischemic event.
摘要:
A method for detecting ischemic states in a patient by contacting a sample of serum, plasma, fluid or tissue with a metal ion capable of binding to metal ion binding sites in the sample to form a mixture, and then detecting the presence of unbound metal ions to determine the occurrence of ischemia. The reagents required to perform the method are incorporated into a test kit.
摘要:
A method for detecting ischemic states in a patient by contacting a sample of serum, plasma, fluid or tissue with a metal ion capable of binding to metal ion binding sites in the sample to form a mixture, and then detecting the presence of unbound metal ions to determine the occurrence of ischemia. The reagents required to perform the method are incorporated into a test kit.